Juan Guzman
Psychiatry · Santa Maria, CANPI 1972521045
Payments from drug & device makers
Across 184 payments — averaging $15.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$389
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$255
- Otsuka America Pharmaceutical, Inc.$167
- E.r. Squibb & Sons, L.L.C.$104
- Teva Pharmaceuticals USA, Inc.$88
- plus $321 from 8 others
What the payments were for
- Food & beverage$2,66196%
- Education$1214%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 117 | $1,458 |
| Sunovion Pharmaceuticals Inc. | 28 | $389 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $255 |
| Otsuka America Pharmaceutical, Inc. | 7 | $167 |
| E.r. Squibb & Sons, L.L.C. | 4 | $104 |
| Teva Pharmaceuticals USA, Inc. | 4 | $88 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $80 |
| Lundbeck LLC | 3 | $66 |
| Axsome Therapeutics, Inc. | 3 | $60 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $25 |
| Alkermes, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
How this compares
$2,782 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 19 | $32,032 |
| Abilify MaintenaAripiprazole | 12 | $24,362 |
| RexultiBrexpiprazole | 15 | $20,960 |
| TrintellixVortioxetine Hydrobromide | 14 | $6,870 |
| Lurasidone Hcl | 19 | $3,800 |
| Divalproex Sodium ErDivalproex Sodium | 15 | $1,066 |
| Lorazepam | 34 | $311 |
| Alprazolam | 41 | $186 |
| Clonazepam | 14 | $97 |
| Sertraline Hcl | 17 | $50 |
| Trazodone Hcl | 19 | $36 |
| Zolpidem Tartrate | 12 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $167 | $45,32227 claims |
| AbbVieVraylar | $1,458 | $32,03219 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $80 | $6,87014 claims |
| Almatica Pharma LLCSertraline Hcl | $22 | $5017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Santa Maria
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.